Tissue biomarkers of breast cancer and their association with conventional pathologic features by Chung, L et al.
1 
 
Tissue biomarkers of breast cancer and their association with conventional 
pathologic features 
 
Running Title: Protein biomarkers in breast cancer tissue 
 
Liping Chung1,†, Sabah Shibli2,†, Katrina Moore2, Elisabeth E Elder3, Frances M Boyle4, 
Deborah J Marsh1, and Robert C Baxter1,* 
 
1Hormones and Cancer Division, Kolling Institute of Medical Research, University of 
Sydney, Royal North Shore Hospital, NSW 2065 Australia; 2Department of Breast 
Endocrine Surgery, Royal North Shore Hospital, NSW 2065 Australia; 3Westmead 
Breast Cancer Institute, Westmead Hospital, NSW 2145 Australia and 4Patricia Ritchie 
Centre for Cancer Care and Research, Mater Hospital, NSW 2060 Australia 
† These authors contributed equally 
 
Corresponding author: Robert C Baxter, DSc 
Kolling Institute of Medical Research, Royal North Shore Hospital 
St Leonards, NSW 2065, Australia 









Background. Tissue protein expression profiling has the potential to detect new 
biomarkers to improve breast cancer (BC) diagnosis, staging, and prognostication. This 
study aimed to identify tissue proteins that differentiate breast cancer tissue from 
healthy breast tissue using protein-chip mass spectrometry and to examine associations 
with conventional pathological features.  
Methods. To develop a training model, 82 BC and 82 adjacent unaffected tissue (AT) 
samples were analysed on cation-exchange protein chips by time-of-flight mass 
spectrometry. For validation, 89 independent BC and AT sample pairs were analysed.  
Results. From the protein peaks that were differentially expressed between BC and AT 
by univariate analysis, binary logistic regression yielded two peaks that together 
classified BC and AT with a ROC area-under-the-curve of 0.92. Two proteins, ubiquitin 
and S100P (in a novel truncated form), were identified by liquid chromatography-
tandem mass spectrometry and validated by immunoblotting and reactive-surface 
protein-chip immunocapture. The combined marker panel was positively associated 
with high histologic grade, larger tumour size, lymphovascular invasion, ER and PR 
positivity, and HER2 overexpression, suggesting that it may be associated with a 
HER2-enriched molecular subtype of breast cancer.  
Conclusion. This independently validated protein panel may be valuable in the 
classification and prognostication of breast cancer patients.  
 





Breast cancer is the most frequently diagnosed cancer, and the leading cause of cancer 
death, in women worldwide (Jemal et al, 2011), with the lifetime risk of developing 
breast cancer estimated to be 1 in 8 in Western countries (Feuer et al, 1993). Patient 
survival has increased steadily over recent decades, attributable in part to advances in 
both mammographic screening (Kopans, 2011) and adjuvant systemic treatment 
protocols (Peto et al, 2012). Whereas pathological features such as tumour size, node 
positivity, hormone receptor positivity and HER2 overexpression have been used to 
guide clinicians’ prescription of adjuvant therapy, true personalised medicine requires 
the development of better biomarkers of risk and response to therapy. 
 
Gene expression profiling is emerging as a tool for classifying breast cancers, guiding 
therapy, and predicting treatment responses (Cheang et al, 2008; Haas et al, 2011). 
However genome and transcriptome analyses alone provide only a partial picture since 
alternative splicing of mRNA, combined with more than 100 unique post-translational 
protein modifications, mean that each gene may give rise to multiple protein species 
(Banks et al, 2000).  
 
Analysing the proteome may provide a more dynamic reflection of the impact of the 
cell’s genetic program on its immediate environment (Aebersold et al, 2005). Cancer 
proteomics encompasses the identification and quantitative analysis of differentially 
expressed proteins relative to healthy tissue counterparts at different stages of disease. 
Proteomic technologies can also be used to identify markers for cancer diagnosis, to 
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monitor disease progression and efficacy of therapy, and to identify new therapeutic 
targets (Srinivas et al, 2001).  
 
Surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) mass 
spectrometry (MS) is a high-throughput proteomic method that involves solid-phase 
extraction of subsets of the proteome prior to analysis by TOF MS (Callesen et al, 
2008). It has the ability to rapidly analyse hundreds of samples, essential for obtaining 
biologically and statistically relevant data in medical proteomic research. A recent 
review of protein profiling studies of breast cancer demonstrates that, despite a 
considerable diversity among these studies, there is a pattern of conformity developing, 
with increasing numbers of studies reporting similar peaks in protein profiles (Galvao et 
al, 2011). This suggests convergence to a set of common discriminatory peaks for breast 
cancer, with reproducibility across different clinical studies.  
 
In this study we have employed SELDI-TOF MS to discover tissue biomarkers of breast 
cancer, and validate them on an independent sample set. We have used two 
immunological methods to verify the identified proteins. Finally, the expression levels 
of these proteins have been associated with clinical pathological variables in order to 
explore their potential value in breast cancer classification and prognosis. 
 
Materials and Methods 
 
Patient Samples 
The study involved 404 patient samples comprised of 202 pairs:  breast tumour tissue 
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(BC) and adjacent unaffected breast tissue (AT) from each subject. For the discovery 
phase, 102 sample pairs were obtained from the Kolling Institute Breast Tumour Bank 
at Royal North Shore Hospital, Sydney Australia.  For independent validation, 100 
sample pairs were provided by the Australian Breast Cancer Tissue Bank, Sydney 
Australia. All breast tissue samples were collected at the day of surgery with prior 
informed consent, and the study was approved by the Human Research Ethics 
Committee of the Northern Sydney Central Coast Area Health Service, Sydney, 
Australia. At the time of surgical resection, tissues were immediately taken to a 
pathologist, who sampled both the tumour itself and adjacent tissue of normal 
appearance. Both samples were snap-frozen in liquid nitrogen within 20 minutes of 
resection and stored at -80°C. Estrogen receptor (ER) and progesterone receptor (PR) 
were scored as either negative or positive by immunohistochemistry, using rabbit 
monoclonal SP1 (Biocare Medical, Concord, CA) and mouse monoclonal Clone 
PgR636 (Dako, Carpinteria, CA), respectively. HER2 status was defined as positive or 
negative by immunohistochemistry using the HercepTest (Dako). Any equivocal result 
using this test was confirmed by FISH. 
 
Tissue Preparation 
Approximately 20 mg of each tissue sample (BC or AT) was prepared for proteomic 
analysis by grinding with a mortar and pestle while frozen in liquid nitrogen, then 
solubilising in 10 volumes of lysis buffer (9.5 M urea, 2% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 1% dithiothreitol). 
Lysates were added to a QiaShredder spin column (Qiagen, Hilden, Germany) and 
centrifuged (12,000 rpm, 5 min) to remove insoluble material. Samples were applied to 
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weak cation-exchange (CM10) protein chips (Bio-Rad Laboratories, Hercules, CA) for 
immediate analysis as described below, or aliquotted and stored at -80°C for future 
analysis. The protein concentration of each extract was determined by BCA Protein 
Assay (Thermo Scientific, Rockford, IL). 
 
Preparation of protein chips  
CM10 protein chips were pre-equilibrated twice with 5 µl of binding buffer (50 mM 
sodium acetate pH 6.0) for 5 min. Protein extracts were diluted 1:5 with binding buffer 
and 5 µl of each diluted extract was pipetted onto the chips. All samples were run in 
duplicate. Chips were then incubated with shaking using a MicroMix 5 (settings: form 
20, amplitude 4), (EURO/DPC Instrument Systems, Flanders, NJ) for 90 min at room 
temperature. Each spot was treated with 2 x 1 µl of 50% cyano-4-hydroxycinnamic acid 
in 50% acetonitrile containing 0.5% trifluoroacetic acid (TFA), and air-dried.  
 
Generation of MS profiles 
Protein profiles were initially obtained using a PBSIIc protein chip reader (Bio-Rad 
Laboratories, Hercules, CA), and in the latter part of the study, a SELDI Enterprise 
Edition protein chip reader (Bio-Rad). Mass spectra were generated for each sample in 
the mass/charge (m/z) range of 1,000-30,000 with a laser intensity setting of 175 
(arbitrary units). The laser was optimised for data collection between 1,000 and 15,000 
m/z, with detector sensitivity set at 8. Peaks below 1,000 m/z were deflected away from 
the detector. Data were averaged from 328 spectra evenly distributed across each spot. 
Mean values from duplicate spectra for each sample were used in all subsequent 
analyses. The m/z value for each peak was determined using external calibration with 
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protein standards including bovine insulin (5734.51 Da), equine cytochrome C (12362 
Da), equine apomyoglobulin (16952.3 Da), and bovine carbonic anhydrase (29023.70 
Da) (Sigma-Aldrich, St. Louis, MO). After calibration, spectra were baseline-subtracted 
and normalised using the total ion current between 1500 and 15,000 m/z. Spectra that 
required a normalisation factor >2 were repeated, and if the high normalisation factor 
persisted, these data were discarded. Peak detection was initially performed using 
Biomarker Wizard Version 3.2.2 (Bio-Rad Laboratories, Hercules, CA) on all peaks 
with signal/noise ratio ≥5 and present in at least 10% of all spectra. Subsequently all MS 
spectra were exported to ProteinChip Data Manger v4.1 used with the ProteinChip 
SELDI System Enterprise Edition (Bio-Rad) to refine the combined data analysis. 
 
MS data analysis 
Data analysis was designed in three stages. For initial discovery, biomarker panels were 
developed on the training data set using 102 BC and AT sample pairs. Cluster analysis 
was performed using Biomarker Wizard version 3.2.2 (Bio-Rad). Univariate analysis of 
individual peaks was performed by Mann-Whitney U test using SPSS (Version 18.0, 
SPSS Inc., Chicago, IL). All protein peaks that significantly discriminated BC from AT 
at p<0.001 were then subjected to multivariate analysis using forward and reverse 
binary logistic regression (SPSS) to develop the training model. The discriminatory 
power of each putative marker was further described using receiver operating 
characteristic (ROC) area-under-the-curve (AUC) analysis. To test protein panels that 
were best able to discriminate BC from AT, 10-fold internal cross-validation was used 
as previously described (Ambroise & McLachlan, 2002; Scarlett et al, 2006). External 




After external validation, to consolidate and unify the initial discovery and validation 
data a further analysis was performed on the combined data sets. This coincided with 
the acquisition of new peak cluster analysis software, ProteinChip Data Manager 
Version 4.1 (Bio-Rad). Similar to the initial discovery phase, both univariate analysis 
using nonparametric statistics and multivariate analysis using binary logistic regression 
were applied, confirming a final two-protein marker panel and allowing calculation of 
overall estimates of sensitivity and specificity, accuracy and ROC AUC values. The 
final stage of data analysis was to re-evaluate the two-protein panel on the separate 
training and validation sets to ensure consistency between the findings from the new 
and original software packages. In this re-testing, all common peaks obtained from the 
combined dataset study were used for each regression analysis to achieve classification 
of tumour samples separately in the training and validation sets.  
 
Protein identification  
For purification of the putative biomarkers, tissue lysates were fractionated using a 
cation-exchange resin (Mustang S, Pall Corp., Ann Arbor, MI) with stepwise pH elution 
from pH 4 to pH 9 in a 96-well filter plate format (AcroPrep™, Pall) as previously 
described (Chung et al, 2009). Proteins of interest in the eluates were monitored by 
SELDI-TOF MS on normal-phase (NP20) chips. Fractions containing an approximately 
8.5 kDa putative biomarker were further purified using reverse phase liquid 
chromatography (LC) on a 250 x 4.6 mm Jupiter 5 µm 300-Å C18 column 
(Phenomenex, Lane Cove, Australia), eluted with a 35-min linear gradient from 15-60% 
acetonitrile in 0.1% TFA at 1.5 ml/min,  followed by separation on 12% SDS-PAGE 
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detected with SYPRO ruby protein stain (Invitrogen, Eugene, OR). Protein bands of 
interest were excised from the gel and analysed using both nanoLC-ESI-MS/MS and 
MALDI-TOF peptide mass fingerprinting by the Australian Proteome Analysis Facility 
(Macquarie University and University of New South Wales, Sydney, Australia). The 
protein peak at 9.2 kDa was purified and identified in a similar manner. 
 
Immunological validation of protein markers  
To detect ubiquitin and S100P by western blotting, BC and AT tissue extracts were 
separated by 12% SDS-PAGE and transferred to PVDF membranes (Bio-Rad). 
Membranes were blocked for 1 h at room temperature with 5% skim milk. Ubiquitin 
was detected by incubating the transferred membranes for 2 h at room temperature on a 
shaking platform with anti-human ubiquitin monoclonal antibody (R&D Systems, 
Minneapolis, MN) at 1:500 dilution in 5% skim milk. For S100P western blotting, 
samples were concentrated 5-fold by centrifugal ultrafiltration with 3-kDa MW cut-off 
(Nanosep 3K Omega, Pall Corp., Ann Arbor, MI) prior to electrophoresis. This was 
necessary to increase detection sensitivity. Concentrated samples were separated and 
transferred, and membranes blocked, as described above, and S100P was detected by 
incubating overnight at 4°C with rabbit anti-human antibody (Invitrogen) at 1:500 
dilution in 5% skim milk. Secondary antibody, peroxidase-linked anti-rabbit IgG 
(1:2000) was added for 1 h at room temperature and the protein bands were visualised 
by enhanced chemiluminescence using the SuperSignal® West Pico Luminol/Enhancer 
solution (Thermo Scientific, Rockford, IL). Western blot data were imaged using the 
LAS 3000 imaging system (Fujifilm, Stamford CT) and the images were analysed with 
Multi-Gauge version 3.0 software (Fujifilm). The quantitative data were normalised to 
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the loading control of b-actin, and analysed using the Wilcoxon signed rank test (SPSS). 
 
To confirm the identity of the m/z 8558 protein peak by protein chip immunocapture, 
pre-activated RS100 protein chips (Bio-Rad) were pre-coupled with 2 µg of monoclonal 
anti-human ubiquitin antibody (R&D) in 50 mM NaHCO3 buffer (pH 9.2) at 4ºC. The 
spots were washed with 50 µM BSA to block the remaining active sites. Tissue lysates 
were diluted 1:5 in buffer containing 50% human serum in 0.1% Triton X-100 in PBS, 
spotted onto RS100 protein chips, and incubated 2 h at room temperature on a shaker to 
achieve optimal binding. After washing with PBS, all spots were rinsed by 50 mM Tris-
HCl, 1 M urea, 0.1% CHAPS, 0.5 M NaCl pH 7.2. After further washing in 5 mM 
HEPES pH 7.2, the spots were coated with 2 x 1 µl of 50% sinapinic acid in 50% 
acetonitrile, 0.5% TFA and air-dried. The chips were then analysed on the SELDI-TOF 
MS. A His-tagged recombinant ubiquitin standard (10.6 kDa; R&D) was used as a 
control. The m/z 9226 protein peak was similarly verified using RS100 protein chips to 
confirm its identity as S100P. Prior to protein chip preparation, all tissue extracts were 
pre-concentrated as described above for Western blotting. RS100 protein chips were 
pre-coupled with 2 µg of rabbit anti human S100P antibody (Invitrogen) in 50 mM 
NaHCO3 buffer (pH 9.2) at 4ºC. The samples were then treated and analysed as 
described above. His-tagged recombinant S100P (12.6 kDa; Novus Biologicals, 
Littleton, CO) was used as a control. 
 
Statistical analysis of clinical features 
The association between levels of the two protein markers, individually and in 
combination, and tumour pathologic variables (tumour size, histological grade, 
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lymphovascular invasion, lymph node involvement, estrogen and progesterone receptor 
status, and HER2 expression) was examined using the Mann-Whitney U test (SPSS). 
Subgroup analyses were also performed, in which lymph node negative (n=84) or 





A total of 202 pairs of tissue samples were used in this study, generating 808 spectra, of 
which 684 (duplicate spectra on 171 pairs of samples) were subjected to full analysis. 
Of the 102 pairs of samples selected for the training stage, 82 pairs were fully analysed. 
Eight of the remaining 20 pairs were excluded on clinico-pathologic grounds: 4 had 
DCIS, 2 had neo-adjuvant treatment and 2 had recurrent tumours; and 12 sample pairs 
were excluded when their mass spectra did not meet normalisation criteria. For the 
validation set of 100 samples pairs, 89 pairs of the subjects were analysed. Seven 
sample pairs were excluded  on clinico-pathologic grounds: 4 had neo-adjuvant therapy, 
1 had metastatic disease and 2 had recurrent disease; 3 sample pairs were lost during 
preparation; and 1 pair was excluded when the mass spectra did not meet normalisation 
criteria. The median age for the patients included in the training and validation sets was 
60 (range 28-92) and 58 (range 27-85), respectively. The clinical pathologic 
characteristics of the tumours including histologic type and grade, size, presence of 
lymphovascular invasion (LVI), hormone receptor (estrogen receptor (ER), 
progesterone receptor (PR)) and human epidermal growth factor receptor 2 (HER-2) 




Selection of protein biomarker panel by MS based protein profiling 
The training set sample pairs (BC and AT) were subjected to MS analysis in duplicate 
to identify putative protein biomarkers that could distinguish tumour from unaffected 
tissue. The 82 sample pairs whose spectra were amenable to normalisation yielded 328 
spectra, from which 53 common peaks were determined by clustering analysis. Of 
these, 14 peaks (m/z 1337, 1705, 1842, 2033, 3790, 3804, 8346, 8548, 8599, 9205, 
9239, 9292, 9641, 12220) were significantly differentially expressed (P<0.005, Mann-
Whitney test). These individual putative biomarkers had ROC-AUC values ranging 
from 0.70 to 0.84. The 14 peaks were tested in forward and reverse binary logistic 
regression analysis with 10-fold cross-validation. This produced a final panel of 3 peaks 
(m/z 1842, 8599, 9292) that classified BC and AT, with ROC AUC of 0.87 as shown in 
Figure 1A (curve Ti).  
 
Independent validation  
The three putative biomarkers were tested using an independent validation set of 100 
sample pairs, of which 89 pairs of spectra (in duplicate, 356 spectra) could be analysed 
after normalisation. For the validation set, 57 common protein peaks were determined 
by clustering analysis. Testing the 3-protein panel derived from the training set on the 
independent sample set of 89 BC and 89 AT samples gave a ROC AUC of 0.91 (Figure 
1A, curve Vi). The sensitivity and specificity were 80.9% and 91%, respectively, and 
overall accuracy was 90%. 
 
Re-analysis of combined data sets 
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To increase the statistical power of the training and validation analyses and confirm the 
results using a newer software version, we combined the data sets into a single analysis 
of all 171 breast tissue sample pairs. Using new clustering analysis software, 
ProteinChip Data Manager Version 4, we found 28 peaks common to all spectra in the 
m/z range of 2,500 to 15,000. Peaks of lower mass were excluded from this analysis 
because the putative marker at m/z 1842 had been determined by LC-MS/MS to be non-
peptide in nature (data not shown). By univariate analysis (Mann-Whitney), the 
significant peaks (p<0.001) were selected with the additional criterion that individual 
ROC-AUC was at least 0.80, summarized in Table 2. Multivariate analysis using binary 
logistic regression again confirmed the two protein markers at m/z 8558 and 9226. The 
difference in m/z values from those determined in the initial training set analysis (m/z 
8599, 9292) is larger than expected and may be attributable to the fact that they are 
averaged from 684 spectra (171 sample pairs in duplicate) rather than 328 spectra (82 
sample pairs in duplicate), re-calibration of standard curves between the initial and 
subsequent analyses, the use of different analysis software, and the relative mass-
inaccuracy of this technique.  Both protein peaks were elevated in BC tissue relative to 
AT. The sensitivity and specificity for the binary classification using the combined 2-
marker panel were 77.2% and 88.9% respectively, with a ROC AUC value of 0.92 
(Figure 1B, curve C).  
 
Re-testing of initial training and validation sets 
For final confirmation of the potential 2-marker panel, it was re-tested on the original 
separate training and validation sets. The sensitivity and specificity of the classification 
for breast tissue biopsy samples were 73.2% and 87.8% respectively in the training set, 
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compared to 80.9% and 91% in the validation set. Their corresponding ROC AUC 
values were 0.86 (curve Tr) and 0.91 (curve Vr) for the training and validation sets, 
respectively (Figure 1C).  
 
Together, these results suggest that two protein biomarkers in combination provide 
efficient discrimination between breast cancer tissue and healthy tissue. Figure 1(D-F) 
demonstrates the performance of the two protein peaks of m/z 8558 and 9226 alone and 
in combination. By paired sample t-test a significant difference between BC and AT 
groups was found for each protein tested separately (Figure 1D and E, n=171, p<0.001). 
For the two-protein combined panel, the mean value was 3.3-fold increased in BC 
compared to AT samples (Figure 1F, n=171, p<0.001).  
 
Identification and verification of putative biomarkers  
Both proteins of m/z 8558 and 9226, retained by weak cation-exchange protein chips, 
were significantly increased in breast cancer tissue. For identification, initial 
purification was carried out using cation-exchange followed by reversed-phase HPLC. 
Eluted fractions were pooled and fractionated by SDS-PAGE, and bands around 8 kDa 
were excised for final identification by LC-MS/MS. Ubiquitin was identified from 6 
peptides (two overlapping) giving 72% sequence coverage. The calculated mass of 
monomeric ubiquitin (8560 Da) was in good agreement with the consensus mass 
obtained experimentally with SELDI (m/z 8558). Similarly, analysis of the marker of 
approximately 9.2 kDa identified it as a fragment or variant of S100P (10,400 Da) from 
two peptides giving 24% sequence coverage relative to full-length S100P 
(Supplementary Figure S1). Notably, the two peptides found in this study were identical 
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to those previously used to identify S100P in a MALDI-MS study of proteins 
upregulated in colorectal cancer (Lam et al, 2010). 
 
Immunological verification of the two protein identities was performed using both 
Western blotting and protein chip immunocapture. For ubiquitin, Western blot 
confirmed differential expression of this protein between BC and AT tissue extracts. 
Figure 2A shows that for BC and AT samples from four randomly selected patients, 
relative overexpression of ubiquitin in the cancer samples was observed. When 
quantitated and analysed for 8 randomly selected sample pairs, the increase in ubiquitin 
in BC was significant (Figure 2B, p=0.017, Wilcoxon signed rank test). The identity of 
this protein as ubiquitin was also verified by immunocapture on RS100 protein chips 
(Figure 2C). The m/z 8558 peak, captured by immobilised ubiquitin antibody and 
displayed by SELDI-TOF MS, was increased in two BC samples in panels (ii) and (iv) 
compared to their corresponding AT samples in panels (i) and (iii), and absent when the 
capture antibody was nonimmune IgG (panel (vi)). Panel (v) shows His-tagged 
recombinant ubiquitin (10.6 kDa) as a control.  
 
Similarly, the expression of S100P was also examined by Western blot in 8 random sets 
of BC and AT samples. Figure 2D shows the Western blot data for four pairs, indicating 
variable levels of this protein between patients, with upregulation in BC samples. When 
quantitated and analysed for all 8 sample pairs, the increase in immunoreactive S100P 
in BC was significant (Figure 2E, p=0.012, Wilcoxon signed rank test). By 
immunocapture using the same S100P antibody immobilised on RS100 protein chips, 
an apparently truncated form (m/z 9226) of S100P protein was observed, similar to that 
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found in the discovery program using CM10 cation-exchange chips. This peak was 
more abundant in BC samples (panels (ii) and (iv)) than in the corresponding AT 
samples (panels (i) and (iii)), and absent when the capture antibody was nonimmune 
IgG (panel (vi)) (Figure 2F). Panel (v) shows His-tagged recombinant S100P (12.6 kDa) 
as a control.  
 
To further confirm the identity of the 9.22 kDa protein as a short form of S100P 
associated with breast cancer, we also isolated this protein from cell lysates prepared 
from MCF-7 breast cancer cells. As shown in Supplementary Figure S2(A-C), this 
protein could be immunoprecipitated from MCF-7 lysates using three different S100P 
antibodies (rabbit monoclonal, mouse polyclonal and rabbit polyclonal). Together with 
the S100P sequence data (Supplementary Figure S1), this unequivocally confirms its 
relationship to S100P. Also visible in the immunoprecipitates was a smaller peak of 
10.48 kDa, presumably representing full-length S100P. The 9.22 kDa form could be 
separated from the full-length protein by further purification on reverse-phase HPLC 
(Supplementary Figure S2D). 
 
Association of two protein biomarkers and their combination with prognostic 
variables 
To investigate the potential prognostic value of ubiquitin and S100P separately and in 
combination in breast cancer, we initially examined the association of each protein with 
variables including tumour stage, nodal stage, histologic type and grade, hormone 
receptor (ER, PR) and HER2 status, and lymphovascular invasion (LVI). As shown in 
Table 3, significant positive associations were seen between expression of the short 
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form of S100P and tumour size, higher grade, LVI, lymph node involvement, hormone 
receptor positive status, and HER2 overexpression, whereas for ubiquitin a significant 
association was only seen with tumour size, grade, and HER2. When analysed together 
(Table 3), the combined panel was significantly associated with tumour histologic 
grade, size, and LVI, and also with ER-positive (ER+) and PR-positive (PR+) status and 
HER2 overexpression (Figure 3). 
 
Since levels of the short form of S100P showed stronger associations than ubiquitin 
with each of the pathological indicators (except for grade), and appeared to point to an 
ER/PR+, HER2 overexpressing phenotype (possibly corresponding to a "HER2-
enriched" molecular subtype (Reis-Filho & Pusztai, 2011)), we undertook further 
analysis of its relationship to these prognostic features. When examined separately for 
ER- and ER+ tumours, high S100P expression in both groups was equally associated 
with tumour size and the presence of LVI (not shown). However, the association 
between S100P and lymph node involvement was only significant for ER- tumours 
(p=0.010).  In contrast, the association between S100P and HER2 overexpression was 
only significant for ER+ tumours (p=0.004), supporting the concept that a high S100P 
level might be associated with a hormone receptor-positive, HER-2 enriched molecular 
subtype.   
 
When examined separately for lymph node-negative and positive tumours, the positive 
association between ubiquitin, the short form of S100P, or the combined panel and LVI, 
ER+ status, and PR+ status was entirely attributable to the lymph node-positive 
tumours. A significant relationship between the combined panel and HER2 
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overexpression was also confined to the lymph node-positive tumours (Supplementary 
Table S1). This subanalysis again points to a link between high expression of the short 
form of S100P in breast tumours, and an ER/PR positive, HER2 overexpressing 
phenotype that has been associated with markers of poor patient outcome without 
treatment. However, because sample numbers are low in some subanalyses, these 




We have used SELDI-TOF MS to discover two proteins that, in combination, show high 
discrimination between breast cancer and healthy breast tissue samples. A limitation of 
the protocol was that no microdissection was used, so that tissue samples could have 
contained heterogeneous cell types. Despite this technical limitation, a robust panel of 
two putative breast cancer biomarkers was discovered, and verified on an independent 
sample set. After purification, the proteins were identified by LC-MS/MS as ubiquitin 
and a truncated form of the S100-family member, S100P.  
 
SELDI-TOF MS has been used previously to discover tissue biomarkers in various 
cancers, although the majority of such studies in breast cancer have examined serum 
rather than tumour tissue. Included among proteins previously identified from breast 
tumour tissue lysates are albumin fragments (Gast et al, 2009) and complement C3a 
(Zhang et al, 2012), both presumably derived from the circulation.  Tissue proteomic 
profiling using SELDI-TOF MS  has also yielded peak clusters that can contribute to 
the classification of breast tumours into molecular subtypes (Brozkova et al, 2008; 
Goncalves et al, 2008) that resemble the luminal A and B, basal, and HER2-like 
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subtypes defined by gene expression analysis (Reis-Filho & Pusztai, 2011).  
 
Of the two breast cancer-associated proteins identified in this study, ubiquitin is a small 
protein of 76 amino acids that is involved both in apoptotic signalling (Vucic et al, 
2011) and transcriptional regulation (Hammond-Martel et al, 2011). Although 
monomeric ubiquitin has been identified in several previous biomarker studies in breast 
cancer, its exact relationship to disease status is unclear. In a SELDI-TOF MS study of 
breast cancer cell lines, we previously discovered ubiquitin as a strongly downregulated 
protein following treatment with chemotherapeutic drugs (Leong et al, 2007). Another 
SELDI analysis found the combination of a high ubiquitin level and low ferritin light 
chain level to be a positive prognostic marker in node negative breast cancer (Ricolleau 
et al, 2006). In contrast, SELDI was also used to show that a protein of similar mass 
(not identified as ubiquitin), was a significant predictive factor for axillary lymph node 
metastasis (Nakagawa et al, 2006). In a MALDI MS analysis of microdissected cells 
from invasive breast cancer and healthy (reduction mammoplasty) tissue, ubiquitin was 
one of a cluster of proteins with increased expression in the cancer tissue (Sanders et al, 
2008).  
 
Several E3 ubiquitin ligases are regarded as tumour suppressors in breast cancer and are 
either mutated or downregulated; in contrast, some others are regarded as oncogenes 
and are overexpressed (Chen et al, 2006). Among key downregulated or mutated E3 
ligases are BRCA1 and Siah1, involved in DNA repair and transcriptional regulation, 
among other functions. E3 ligases downregulated in cancer are involved in both 
monoubiquitination (Hahn et al, 2012) and polyubiquitination (Wen et al, 2010), and 
low expression of the E3 ligase Siah1 is associated with poorer disease-free survival in 
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women with breast cancer (Confalonieri et al, 2009). It may be speculated that the 
increased level of monomeric ubiquitin that we observed associated with larger 
tumours, higher grade, and HER2 overexpression, but not with other pathological 
markers (Table 3), reflects a decrease in the activity of some key ubiquitin ligase 
complexes. Interestingly, a component of the Siah1 ubiquitination complex, calcyclin-
binding protein/Siah1-interacting protein (CacyBP/SIP), has increased expression in 
breast cancer tissue compared to adjacent unaffected breast tissue, and is associated 
with markers of poor prognosis (Wang et al, 2010). CacyBP/SIP is a documented 
binding partner of S100P (Filipek et al, 2002), raising the possibility that the disruption 
of ubiquitination pathways in breast cancer might be involved in the increased levels of 
both of the cancer-related biomarkers discovered in our study. 
 
In contrast to the relatively weak associations observed between elevated ubiquitin 
levels and tumour size, higher grade, and HER2 overexpression, a high level of the 
novel short form of S100P was positively associated with larger tumours, higher grade, 
LVI, lymph node involvement, ER/PR positivity, and HER2 overexpression. Of the two 
identified biomarkers, S100P made the stronger contribution towards the association of 
the combined panel towards each of these pathological features apart from tumour 
grade. Since the association between S100P and HER2 overexpression was exclusive to 
the ER+ tumours (p=0.004), and absent in the ER- subgroup, a high tissue S100P level 
may point to a group of tumours with high ER/PR positive status, HER2 
overexpression, and – given the association with size, grade and LVI – relatively poor 
outcome, although our study did not include actual outcome variables. This corresponds 
most closely to the "HER-enriched" breast cancer subtype (Reis-Filho & Pusztai, 2011; 
Slamon et al, 1987), and suggests that S100P might have potential  both in the  
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classification of breast cancer, and possibly as a target for therapy.  
 
S100P is a member of the calcium-binding S100 protein family that contain a 
characteristic structural domain known as the EF hand motif (Marenholz et al, 2004). 
There are at least 24 homologous S100 proteins with similar subcellular localisation, but 
differing in expression pattern and function (Marenholz et al, 2004). S100 proteins are 
low molecular weight (10-12 kDa) acidic proteins that exist as intracellular or secreted 
homo- or hetero-dimers with composition depending on the abundance of individual 
family members and the cellular context (Santamaria-Kisiel et al, 2006). Although the 
factors that regulate S100P have not been studied extensively, DNA microarray studies 
have included S100P among panels of genes upregulated by estradiol (Terasaka et al, 
2004), progesterone (Bray et al, 2005) and HER2 overexpression (Mackay et al, 2003). 
These preliminary gene expression reports are consistent with the clinical associations 
we observed between high S100P levels and ER/PR positive and HER2 overexpressing 
tumours. 
 
S100P has been associated with the progression of several types of cancer including 
pancreatic, prostate, colorectal and breast, through effects on tumour growth and 
metastasis (Jiang et al, 2011; Lam et al, 2010). At least some of its effects have been 
shown to be mediated through extracellular interaction with RAGE (receptor for 
activated glycation end products) (Arumugam et al, 2004). Several studies of pancreatic 
cancer-related molecular profiles have identified S100P as a significantly elevated gene 
(Crnogorac-Jurcevic et al, 2003; Logsdon et al, 2003), whose upregulation is an early 
event in the development of pancreatic cancer (Whiteman et al, 2007). In breast cancer, 
S100P was linked to immortalisation of breast epithelial cells in vitro and both tumour 
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progression (Guerreiro Da Silva et al, 2000; Schor et al, 2006) and early relapse 
(Barraclough et al, 2010) in patients. Survival of breast cancer patients with S100P 
positive carcinomas was significantly worse than those negative for S100P 
(Barraclough et al, 2009; Wang et al, 2006).  S100P was also prominent among genes 
over-expressed in primary breast cancer cells from high-grade tumours (Dairkee et al, 
2009). In contrast, gastric cancers that stain positive for S100P are associated with a 
better patient outcome that those that are negative for S100P (Jia et al, 2009).  
 
The S100P form detected in our study by MS on cation-exchange chips, and confirmed 
by MS after selective binding to immobilised S100P antibody, appeared at a m/z value 
of 9226. This contrasts with the expected size of mature S100P which contains 95 
amino acids and has a molecular mass of 10.4 kDa, suggesting that the observed S100P 
species detected by MS is a previously unreported truncated form of this protein. An 
amino-terminally truncated form of S100P, termed migration-inducing gene 9 protein or 
MIG9, has been reported in GenBank (Protein Accession No. AAS00487.1), described 
as an alternatively spliced product. The predicted protein is identical to S100P[8-95] 
except for an isoleucine to methionine substitution at S100P residue 12 (MIG9 residue 
5), and has a predicted molecular mass of 9.64 kDa. If the true translation start site is 
methionine-5, the predicted molecular mass would be 9.21 kDa and could explain our 
observed peak on SELDI-TOF MS.  Importantly, it is unlikely that the many immuno-
histochemical studies that have measured S100P distribution in patient tissues could 
distinguish between S100P and these truncated forms. Mass spectrometry would be the 
optimal method for this identification. We have therefore identified for the first time a 




In conclusion, this study has discovered two protein biomarkers, ubiquitin and S100P 
— the latter as a novel truncated isoform — that, in combination, provide high 
discrimination between breast cancer tissue and healthy breast tissue. Correlation with 
clinical pathologic variables demonstrated that high values for the two-protein panel 
were associated with high histologic grade and tumour size, presence of lymphovascular 
invasion, ER and PR positive status, and HER2 overexpression. We propose that this 
independently validated protein biomarker panel may indicate a HER2-enriched breast 
cancer subtype with poor prognosis, and that measurement of S100P, in particular, may 
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Table 1. Patient Characteristics 
 
Characteristics Training Set  Validation Set 
No. of patients 82 89 
Age (median) 60 58 
Histologic type    
Ductal (IDC) 68 76 
Lobular (ILC) 10 10 
Other 4 3 
Histologic grade   
grade 1 7 11 
grade 2 32 27 
grade 3 43 49 
Missing  2 
Tumour size   
≤ 2 cm 29 28 
≥ 2 cm 53 59 
Missing  2 
Estrogen receptor   
positive 56 64 
negative 25 23 
Missing 1 2 
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Progesterone receptor   
positive 44 54 
negative 38 33 
Missing 0 2 
HER2 overexpression   
positive 15 16 
negative 57 63 
Missing 10 10 
Lymphovascular invasion   
present 34 35 
absent 48 54 
Lymph node involvement   
positive 42 43 
negative 40 44 
Missing   2 
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; 
ER, Estrogen receptor; PR, Progesterone receptor; HER2, Human 
epidermal growth factor receptor 2 
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Table 2. Summary of data analysis 
      
Data Analysis 
Stage 





No. of patients 82 89 171 82 89 
MS profile No. 164 178 342 164 178 
ROC-AUC 0.87 0.91 0.92 0.86 0.91 
Classification* Sens 75.6% 
Spec 91.5 %  
Sens 80.9% 
Spec 91%  
Sens 77.2% 
Spec 88.9 %  
Sens 73.2% 
Spec 87.8 %  
Sens 80.9% 
Spec 90.0 % 
 
* Sensitivity (Sens) and specificity (Spec) 
 




Table 3. Association of two protein markers and their combination with tumour 









Tumour size (T ≤ 2 cm, n=57 vs.  
T > 2 cm, n=112) 
0.024 0.009 0.008 
Grade (G1, n=18 vs. G3, n=92) .026 .032 .016 
LVI (present, n=69 vs.   
absent, n=102) 
0.106 0.011 0.044 
ER (positive, n=120 vs.  
negative, n=48) 
0.059 0.004 0.016 
PR (positive, n=98 vs.  
negative, n=71) 
0.067 0.006 0.022 
HER2 (positive, n=31 vs. 
  negative, n=120) 
0.033 0.002 0.009 
LN* (positive, n=85 vs. 
negative, n=84) 
0.315 0.027 0.121 
Histologic type (IDC, n=144 vs.  
ILC, n=20)  
0.607 0.765 0.708 
	





Figure 1. Performance of two protein peaks individually and in combination. (A) 
The ROC area-under-curve (AUC) after cross-validation was 0.87 (Ti) for the 
combination of peaks at m/z 1842, 8599 and 9292. For the independent validation 
sample set, the average value of ROC-AUC was 0.91 (Vi). (B) Combination of the 
discovery and validation sets. The sensitivity and specificity of the combination peaks 
of m/z 8558 and 9226 were 77.2% and 88.9% with a ROC-AUC value of 0.92. (C) 
Retesting of initial training and validation sets. ROC-AUC values for these tests were 
0.86 (Tr) and 0.91 (Vr) for training and validation sets, respectively. (D) Mean peak 
intensity values ± SEM (Normal vs. Cancer) for the marker at m/z 8558; (E) Mean 
values ± SEM for the marker at m/z 9226, and (F) Mean values ± SEM for the two 
markers combined. For the comparisons in panels D-F, n=171, p<0.001.  
 
Figure 2. Immunological validation of ubiquitin and S100P. (A) For ubiquitin, four 
BC and corresponding AT extracts were analysed by immunoblotting, indicating 
relative upregulation of ubiquitin in some breast cancer patients. b-Actin is shown as a 
loading control. (B) Densitometric analysis of ubiquitin Western blots of 8 sample pairs. 
Box plot shows median, upper and lower quartiles; lines show maximum and minimum 
values. P=0.017, Wilcoxon signed rank test. (C) MS spectra of proteins bound to 
immobilised mouse anti-ubiquitin antibody. Samples were (i) patient #1 normal tissue, 
(ii) patient #1 cancer tissue, (iii) patient #2 normal tissue, (iv) patient #2 cancer tissue, 
(v) recombinant His-tagged ubiquitin, and (vi) patient #2 cancer tissue, mouse IgG 
control. Arrow indicates the mass of monomeric ubiquitin, m/z 8558. N=normal tissue, 
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C=cancer tissue. (D) For S100P, four BC and corresponding AT extracts were analysed 
by immunoblotting, indicating relative upregulation of S100P in some breast cancer 
patients. b-Actin is shown as a loading control. (E) Densitometric analysis of S100P 
Western blots of 8 sample pairs. Box plot shows median, upper and lower quartiles; 
lines show maximum and minimum values. P=0.012, Wilcoxon signed rank test. (F) 
MS spectra of proteins bound to immobilised rabbit anti-S100P antibody. Samples were 
(i) patient #3 normal tissue, (ii) patient #3 cancer tissue, (iii) patient #4 normal tissue, 
(iv) patient #4 cancer tissue, (v) recombinant His-tagged S100P, and (vi) patient #4 
cancer tissue, rabbit IgG control. Arrow indicates the mass of the S100P form of m/z 
9226. N=normal tissue, C=cancer tissue. 
 
Figure 3. Association of the combined panel with histo-pathologic variables. Higher 
expression of the combined panel was significantly associated with higher histologic 
grade (p=0.016),  higher tumour size (p=0.008), and weakly with the presence of LVI 
(p=0.044). The panel was also relatively increased in tumours that were positive for 
estrogen receptors (p=0.016),  progesterone receptors (p=0.022), and HER2 
overexpression (p=0.009).  Box plots show median, upper and lower quartiles; lines 
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P62988 (UBIQ_HUMAN)  MW = 8560, Ubiquitin 
 MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKEGIPPDQ QRLIFAGKQL 
EDGRTLSDYN IQKESTLHLV LRLRGG!
Supplementary Figure S1 
Figure S1. Tryptic peptides (underlined in the full sequence) used to identify ubiquitin and S100P by 
MASCOT searching.  
Supplementary Figure S1 
P25815 (S100P_HUMAN) MW= 10400, S100P 
MTELETAMGM IIDVFSRYSG SEGSTQTLTK GELKVLMEKE LPGFLQSGKD 
KDAVDKLLKD LDANGDAQVD FSEFIVFVAA ITSACHKYFE KAGLK  
Supplementary Figure S2 
Figure S2. SELDI-TOF MS profiles on normal-phase (NP20) chips, showing protein peaks 
immunoprecipitated from MCF-7 breast cancer cell lysates using three different S100P 
antibodies. A:  Rabbit monoclonal (Epitomics); B: Mouse polyclonal (Abnova); C: Rabbit 
polyclonal (Invitrogen). D: Immunoprecipitate from rabbit polyclonal antibody (Invitrogen) 
after further purification by reverse-phase HPLC. 
 
Methods 
Immunoprecipitation. MCF-7 cells were lysed in buffer containing 20 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100. To isolate S100P, 25 µl (0.75 
mg) of Protein G Dynabeads (Invitrogen) were incubated with S100P antibody (rabbit 
monoclonal #5263-1, 5.45 µg, Epitomics; MaxPab mouse polyclonal #H0006286-B01P, 5 
µg, Abnova; or rabbit polyclonal #18-0046, 4.68 µg, Invitrogen) for 30 min at room 
temperature with rotation. Following two washes with PBS pH 7.4 containing 0.02% Tween 
20, the bound antibody-bead complex was added to 50 µl of cell lysate, mixed by vortexing, 
and incubated for 2 h at room temperature with rotation. The beads were washed three times 
with PBS pH 7.4 and bound proteins eluted with 100 mM glycine, pH 2.8. Fractions were 
monitored by SELDI-TOF MS on normal-phase NP20 protein chips (Bio-Rad).  
Reverse-phase HPLC. Immunprecipitated proteins were applied to a 4.6 x 250 mm C18 
column (Jupiter, 5 µm, 300 Å) and eluted at 1.5 ml/min with a 30-min gradient from 15% to 

















Supplementary Table S1. Association of two protein markers and their combination with tumor histopathologic variables.   
 
Tumor variables 
Lymph Node Negative (n=84)  Lymph Node Positive (n=85) 












≤2 cm vs. >2cm 43 vs. 41 0.059 0.013 0.025  13 vs. 68 0.057 0.066 0.015 
Grade 
G1 vs. G3 10 vs. 45 0.775 0.665 0.692  8 vs. 47 0.875 0.984 0.338 
LVI 
Present vs. Absent 15 vs. 69 0.312 0.249 0.404  68 vs. 17 0.005 0.001 0.002 
ER 
Positive vs. Negative 62 vs. 21 0.757 0.173 0.383  58 vs. 23 0.011 0.026 0.004 
PR 
Positive vs. Negative 54 vs. 28 0.284 0.053 0.112  44 vs. 23 0.001 <0.001 <0.001 
HER2 
Positive vs. Negative 10 vs. 34 0.248 0.054 0.139  22 vs. 46 0.064 0.056 0.041 
 
 
 
